Takeda Partner BridGene Biosciences Brings in $38.5 Million Series B

July 28, 2022

BridGene Biosciences

The small biotech Bridgene Biosciences has scored another funding win, this time to the tune of $38.5 million in a Series B. Last year, the company netted $12 million in a Series A and secured a partnership with Takeda that could amount to half a billion dollars. BridGene intends to use the money to develop it’s IMTAC platform, a small molecule screening tool for oncology research.

According to Tyler Patchen, “The Series B will give BridGene a runway of two years, with  execs hoping to have a clinical trial up and running by 2024. The company is also looking to expand its headcount. Cao said he is looking to have around 40 employees by the middle of next year, up from the current total of 24.”

To read more, click here.

(Source: Endpoints News, July 27th, 2022)

Share This Story!